Aclaris Therapeutics Inc   (ACRS)
Other Ticker:  
Price: $1.2200 $0.06 5.172%
Day's High: $1.24 Week Perf: -0.81 %
Day's Low: $ 1.16 30 Day Perf: -13.48 %
Volume (M): 632 52 Wk High: $ 11.12
Volume (M$): $ 771 52 Wk Avg: $5.25
Open: $1.18 52 Wk Low: $0.59

 Market Capitalization (Millions $) 85
 Shares Outstanding (Millions) 70
 Employees -
 Revenues (TTM) (Millions $) 31
 Net Income (TTM) (Millions $) -88
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 1

Aclaris Therapeutics Inc
Aclaris Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address unmet needs in dermatology and immunology. The company has a diverse pipeline of drug candidates targeting various skin and hair disorders, including alopecia areata, vitiligo, and common warts. Aclaris Therapeutics aims to provide effective and safe treatment options for patients suffering from these medical conditions. The company's research and development efforts are centered on discovering novel compounds and utilizing advanced technologies to improve patient outcomes.

   Company Address: 701 Lee Road, Suite 103 Wayne 19087 PA
   Company Phone Number: 324-7933   Stock Exchange / Ticker: NASDAQ ACRS


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Aclaris Therapeutics Inc

2. Aclaris Therapeutics Inc: Paving the Way for Innovative Healthcare Solutions

The strategic business review initiated by Aclaris Therapeutics aims to identify areas of improvement and optimize its resources to drive growth and create value for shareholders. The company is focused on leveraging its expertise in developing drug candidates for immuno-inflammatory diseases to capitalize on emerging opportunities in the healthcare market. With a strong pipeline of innovative products, Aclaris Therapeutics is well-positioned to address unmet medical needs and enhance patient outcomes.
Despite the recent financial challenges, Aclaris Therapeutics remains committed to advancing its mission of delivering groundbreaking therapies to patients in need. The company's dedication to research and development underscores its long-term vision for sustainable growth and success in the pharmaceutical industry. By investing in innovative healthcare solutions, Aclaris Therapeutics aims to expand its market presence and solidify its reputation as a leading provider of pharmaceutical preparations.

Management Changes

Aclaris Therapeutics: Charting a Path to Financial Reinvention and Leadership Reinforcement

Published Tue, Jan 16 2024 12:01 PM UTC

Aclaris Therapeutics, a prominent player in the healthcare sector, has recently announced significant leadership changes and a strategic business review. The decision comes after a period of financial underperformance, with the company's year-to-date stock performance showing a decline of 12%. Additionally, Aclaris Therapeutics reported a net loss of $115 million f...

Clinical Study

JAK Inhibitor ATI-1777: A Promising New Development in Atopic Dermatitis Treatment.

Published Wed, Jan 10 2024 12:00 PM UTC

??Abstract: Aclaris Therapeutics recently announced positive top-line results from their four-week Phase 2b trial of ATI-1777, an investigational topical soft Janus kinase (JAK) inhibitor, in patients with mild to severe atopic dermatitis (AD), with the drug having achieved a statistically significant result in the primary efficacy endpoint at week four.??Atopic Dermatitis (...

Product Service News

Aclaris Therapeutics Braces for a Challenging Period: Announces Workforce Reductions Amid Anticipated Phase 2b Trial Results

Published Tue, Dec 19 2023 9:01 PM UTC

In a pivotal corporate update, Aclaris Therapeutics Inc., a pharmaceutical company specializing in dermatological treatments, provided significant insights into their ongoing efforts and the systemic changes anticipated in their operations. Primarily, the company disclosed its tentative results for the ATI-1777 Phase 2a Trial and news about an unavoidable reduction in i...

Licensing Agreement

Aclaris Therapeutics Teams Up with Sun Pharma in a Game-Changing Patent License Agreement for Alopecia Treatment.

Published Tue, Dec 5 2023 9:01 PM UTC

Aclaris Therapeutics Partners with Sun Pharma in Patent License Agreement for AlopeciaIn a significant move towards revolutionizing treatment options for alopecia, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a leading clinical-stage biopharmaceutical company, announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma) on December 5, 2...


Aclaris Therapeutics Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Aclaris Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Aclaris Therapeutics Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com